

**Updates from ORD
National Center for Environmental
Assessment (NCEA) & Integrated Risk
Information System (IRIS)**

Tina Bahadori, NCEA Director
Kris Thayer, NCEA IRIS Division Director

EPA Science Advisory Board
August 29-30, 2017

NCEA's unique and essential role:


- Experienced and multi-disciplinary teams integrating and synthesizing findings from large bodies of evidence to develop scientific assessments
- Translating research and communicating scientific findings to inform Agency and State and local agency partner decisions

Critically positioned between:

- Researchers – inside and outside EPA -- who are generating new findings and data

AND


- EPA Program and Regional offices, states and local agencies who must make regulatory, enforcement, and remedial actions and decisions



<https://www.epa.gov/risk>



NCEA Human Health Risk Assessment








NCEA Environmental Assessments

- **High profile assessments support regulatory and policy decisions for Office of Water, Regions and States**

- Support to OW & Regions to develop benchmarks for conductivity
- Assessment of Mountaintop Mining that provided support for OW guidance and action under CWA 404(c)
- Evaluation of potential impacts of large-scale mining activities on salmon resources in Bristol Bay, Alaska



- Connectivity of Waters of the United States: Synthesis of the scientific evidence on the connectivity of streams, wetlands, and open waters to downstream waters; scientific foundation for rulemaking to clarify CWA jurisdiction.
- Hydraulic Fracturing Drinking Water Assessment

NCEA continues to work with OW to translate science to effective policy, guidance, rules, and regulatory action.



New Leadership Structure in NCEA

- **In January 2017, EPA appointed new leadership to the National Center for Environmental Assessment and to its IRIS Program.**
 - With significant experience in the chemical industry, and formerly the Director of ORD's Chemical Safety for Sustainability National Research Program, the new NCEA Director brings knowledge of TSCA, innovative applications of computational toxicology, and exposure science.
 - As a recognized leader in systematic review, automation, and chemical evaluations, the new IRIS Program Director brings experience in early partner and stakeholder engagement and input, and demonstrated actions to increase capacity and transparency in assessments.
- **Improved responsiveness and accountability through Senior Leadership Team**
 - NCEA IO
 - Divisions
 - Integrating across the spectrum of human and ecological RA practices




- **Created in 1985 to foster consistency in the evaluation of chemical toxicity across the Agency.**
- **IRIS assessments contribute to decisions across EPA and other health agencies**
- **Toxicity values**
 - **Noncancer: Reference Doses (RfDs) and Reference Concentrations (RfCs).**
 - **Cancer: Oral Slope Factors (OSFs) and Inhalation Unit Risks (IURs).**
- **IRIS is the only federal program to provide toxicity values for both cancer and noncancer effects.**
- **IRIS assessments have no direct regulatory impact until they are combined with**
 - **Extent of exposure to people, cost of cleanup, available technology, etc.**
 - **Regulatory options, which are the purview of EPA's program offices.**




IRIS Addresses Agency Priorities and Mandates

↑
IRIS
↓

- Clean Air Act (CAA)
- Safe Drinking Water Act (SDWA)
- Food Quality Protection Act (FQPA)
- Comprehensive Environmental Response, Compensation, and Liability Act (CERCLA)
- Resource Conservation and Recovery Act (RCRA)
- Toxic Substances Control Act (TSCA)




Broad
Input to
Support



- Agency Strategic Goals
- Children's Health,
Environmental Justice

2014



“Overall, the committee finds that substantial improvements in the IRIS process have been made, and it is clear that EPA has embraced and is acting on the recommendations in the NRC formaldehyde report. The NRC formaldehyde committee recognized that its suggested changes would take several years and an extensive effort by EPA staff to implement. Substantial progress, however, has been made in a short time, and the present committee’s recommendations should be seen as building on the progress that EPA has already made.” [p.9]

“ . . . the IRIS program has moved forward steadily in planning for and implementing changes in each element of the assessment process. The committee is confident that there is an institutional commitment to completing the revisions of the process . . . Overall the committee expects that EPA will complete its planned revisions in a timely way and that the revisions will transform the IRIS Program.” [p.135]



Previous Phased Improvements to the IRIS Program

- The IRIS Program has taken prior, incremental steps to address the NAS recommendations, including:
- Revising the structure of assessments to enhance the clarity and transparency of presentation:
 - detailing the methods underlying each step of draft development (e.g., literature search strategy)
 - restructuring the document into separate hazard identification and dose-response chapters
 - replacing lengthy study summaries with synthesis text, supported by standardized tables and graphs
- Implementing “IRIS Enhancements”, which laid out an updated process for developing and reviewing assessments that increases public input and peer consultation at earlier stages of assessment development, and clarifies processes for considering new evidence and scientific issues



Previous Phased Improvements to the IRIS Program

- Establishing the **SAB Chemical Assessment Advisory Committee (CAAC)** to strengthen peer review advice
 - 5 IRIS assessments completed **CAAC** review since 2014
- Contracting with the **NAS** to arrange for independent experts to attend public meetings on science topics
- Restructuring the IRIS program to create expertise-specific workgroups and improved assessment oversight



How is IRIS Focusing?


- **Increase transparency and full implementation of systematic review**
 - implement using approaches that foster consistency across the IRIS program; many active and all new starts address ALL SR-related recommendations of 2014 NRC report
- **Modernize the IRIS Program**
 - through automation and machine learning to expedite systematic review, incorporation of emerging data types
- **Modularize product lines**
 - implement a portfolio of chemical evaluation products that optimize the application of the best available science and technology. These products will allow IRIS to remain flexible and responsive to clients within the EPA as well the diverse collection of stakeholders beyond EPA, including states, tribal nations, and other federal agencies.
- **Enhance accessibility**
 - provide outreach and training to make systematic review practices ubiquitous and more accessible; enhance data sharing through publicly available software platforms for assessments developed by EPA, other federal and state agencies, industry, academia and other third-parties.


Next Generation IRIS

- IRIS in the 21st Century – implement recommendations of the NAS 2017 report, Using 21st Century Science to Improve Risk-Related Evaluations;
- Collaborate with EPA's National Center for Computational Toxicology (NCCT) to build expert-judgement case studies that inform assessment development and fill gaps in assessments, especially for data poor chemicals; inform where resources should be strategically invested to generate additional data.

Improved Management Practices

- Create efficiencies – engage other agencies to share common practices, data, and tools, and more efficiently leverage resources across the federal government.
- Improve timeliness and responsiveness – deploy program and project management tools to more effectively and efficiently utilize human resources to ensure timely delivery of products.





A structured and documented process for transparent literature review^{1,2}

“... systematic review is a scientific investigation that focuses on a specific question and uses explicit, pre-specified scientific methods to identify, select, assess, and summarize the findings of similar but separate studies. The goal of systematic review methods is to ensure that the review is complete, unbiased, reproducible, and transparent”

¹ Procedures for Chemical Risk Evaluation Under the Amended Toxic Substances Control Act. EPA-HQ-OPPT-2016-0654. https://www.epa.gov/sites/production/files/2017-06/documents/prepubcopy_tsca_riskeval_final_rule_2017-06-22.pdf

² Institute of Medicine. Finding What works in Health Care: Standards for Systematic Reviews. p.13-34. The National Academies Press. Washington, D.C. 2011




“....one disadvantage in conducting a systematic review is that it can be time and resource intensive, particularly for individuals that have not previously conducted a systematic review.” [p.157]

“The committee discussed at length whether it could provide EPA with advice about when a systematic review should be performed but decided it could not be more specific because that decision will depend on the availability of data and resources, the anticipated actions, the time frame for decision making, and other factors.” [p.157]

“The committee also recognized that it might be advantageous for EPA to build on existing systematic reviews that are published in the peer-reviewed literature.” [p.157]

“The committee recognizes that the methods and role of systematic review and meta-analysis in toxicology are evolving rapidly and EPA will need to stay abreast of these developments, strive for transparency, and use appropriate methods to address its questions.” [p.157]


- **Standard operating procedures (IRIS Handbook) and chemical-specific protocols**
- **Use of specialized software applications and automation**
- **Targeted focus, especially for evidence-rich topics**
 - **Make better use of well-conducted existing assessments as starting point**
- **Multiple assessment products (“modularity”)**
- **Solicit early feedback during scoping and problem formulation via assessment plans**
 - **Summary of scoping and initial problem formulation conclusions, objectives and specific aims of the assessment, draft PECO (Population, Exposure, Comparators, and Outcomes) framework that outlines the evidence considered most pertinent to the assessment, and identification of key areas of scientific complexity**
- **Utilize iterative protocols to ensure focus on best-available and most-informative evidence as the assessment progresses**



These documents should address previous discussions and suggestions made from during previous SAB reviews related to transparency of literature review and other aspects of the assessment (e.g., ammonia, trimethylbenzenes, ETBE/TBA)



Systematic Review Tools





HAWC: Data Extraction Animal Bioassay



Contact About Public Assessments Your HAWC

Home / Uranium UHA (2017) / Verde-Casero et al. 2012 / Growth drinking water bioassay / Postnatal period Sprague-Dawley male rats / Create endpoint

SELECTED ASSESSMENT

ASSESSMENT

ASSESSMENT

Literature review

Management dashboard

Study list

Risk of bias

Endpoint list

Visualizations

Executive summary

Notes and tags

Download datasets

Create new endpoint

Create a new endpoint. An endpoint may should describe one measure-of-effect which was measured in the study. It may or may not contain quantitative data.

Endpoint name*

Short-text used to describe the endpoint. Should include observation-time, if multiple endpoints have the same observation time.

System

Organ (and tissue)

Effect

Effect subtype

Relevant biological system

Relevant organ; also include tissue if relevant

Effect, using common vocabulary

Effect subtype, using common-vocabulary

Additional tags

Diagnostic

Any additional descriptive-tags used to categorize the outcome

Diagnostic or method used to measure endpoint (if relevant)

Observation time

Observation time units*

Observation time text

Nominal value of the time an observation was reported; optional. Should be recorded if the same effect was measured multiple times

not-reported

Text for reported observation time (ex. "60-90 PCR")

☒ Data reported

Dose-response data for endpoint are available in the literature source

☒ Data extracted

Dose-response data for endpoint are extracted from literature into HAWC

☒ Values estimated

Response values were estimated using a digital reader or other methods

Dataset type*

Variance type*

Continuous

SD

[ALL PUBLIC ASSESSMENTS](#)
[OVERVIEW](#)
[OVERVIEW](#)
[Literature review](#)
[Management dashboard](#)
[Study list](#)
[Risk of bias](#)
[Exposure list](#)
[Visualizations](#)
[Executive summary](#)
[Comments](#)
[Download datasets](#)

Create new study-population

Create a new study population. Each study-population is associated with an epidemiology study. There may be multiple study populations with a single study, though this is typically unlikely.

Name*

Design*

Age profile*

Source

Age profile of population (ex. adults, children, pregnant women, etc.)

Population source (ex. general population, environmental exposure, occupational cohort)

Country*

Region

State

Eligible N

Invited N

Participant N

Inclusion criteria

Exclusion criteria

Confounding criteria

Comments

Make including criteria, etc.



Cancel



Epidemiology: Click to See More Display

"Identifying Research Needs for Assessing Safe Use of High Intakes of Folic Acid"

Draft: Eczema, Prospective Studies

Study	Population Name	Assessed Outcome Name	Exposure Measure	Exposure Comparison Statistical
Bekkers, 2012	PIAMA birth cohort, 1996-1997	Eczema	Bekkers, 2012 / PIAMA birth cohort, 1996-1997 / Folic acid containing supplements during pregnancy / Eczema	
		Assessed outcome	Eczema	
		Population description	PIAMA birth cohort, 1996-1997	
		Diagnostic	self reported	
		Diagnostic description	an itchy rash that came and went on typical eczema sites (the folds of the elbows or behind the knees, around ears or eyes or in front of the ankles)	
		When finding supported?	inconclusive	
		Prevalence incidence	0.180 - 0.147, reported by age (Table 2)	
		Statistical metric presented	adjusted prevalence ratio	
		Statistical metric description	Logit models, generalized estimating equations (GEE) with a log link function were used to obtain prevalence ratios (PRs). GEEs take into account the correlation between repeated measurements in the same individual. An independent correlation structure was used for the other outcome measures. An interaction term with age was included in the GEE model to allow the association between maternal use of supplements and the outcomes to vary with age.	
		Statistical power sufficient?	not reported or calculated	
		Dose response trend?	not applicable	
		Effect type	dermal, hypersensitivity, immunological	
		Adjustment factors	<ul style="list-style-type: none">maternal allergymaternal educationmaternal smoking during pregnancymaternal older siblings	
Dunstan, 2012	Pregnant women in Western Australia	Eczema		
Dunstan, 2012	Pregnant women in Western Australia	Eczema		
Dunstan, 2012	Pregnant women in Western Australia	Eczema		
Magdeijns, 2011	KOALA Birth Cohort Study	Eczema until	Exposure group	N Adjusted prevalence ratio p-value
			No folic acid use	1809 1.00 n/a
			"low" and/or "high" supplementation ^a	1996 0.96 (0.87, 1.08) n/a
			Five-phase vitamin supplementation	207 1.07 (0.69, 1.29) n/a
			Multivitamin or vitamins B or/and/or supplement	199 1.04 (0.62, 1.33) n/a
			^a Folic acid was adjusted by INMKT assessment authors	

Eczema

No folic acid use

Folic acid-only supplements


Pre-natal vitamin supplements

Multivitamin or vitamin B or/and/or supplement

Adjusted prevalence ratio


NTP Monograph: Identifying Research Need
51. <http://ota.nhs.uk/nhs.gov/ota/what/folicacid>

NTP Monograph: Identifying Research Need
51. <http://ntp.niehs.nih.gov/ntp/ohat/folicacid/>





Systematic Review Collaborations in Environmental Health





IRIS Multi-Year Agenda

Developing Agenda

- Released to the public December 2015
- Survey EPA program and regional offices for their assessment needs
- Estimate the resources needed for each assessment by science discipline
- Discuss with senior EPA officials how to meet the most high-priority needs
- Allocation of IRIS resources based on the plan
- Evaluate annually for continued relevance

Group	Chemicals
1	Manganese
	Mercury/methylmercury
	Nitrate/nitrite
	Perfluoroalkyl compounds
	Vanadium and compounds
2	Acetaldehyde
	Ammonia (oral)
	Cadmium and compounds
	Uranium
3	Di-(2-ethylhexyl) phthalate
	Dichlorobenzene isomers
	Methyl t-butyl ether (MTBE)
	Nickel and compounds
	Styrene



September 27-28, 2017 SAB CAAC

Systematic review and
implementation within the IRIS
Program

Kris Thayer and Andrew
Kraft
*National Center for
Environmental Assessment*

Discussion

Kenneth Ramos and CAAC
Members

Public Comments

Registered Speakers

Assessment Plans and their Role within the IRIS Process		
Multi-year agenda group 1		→ Nitrates/Nitrites
Discussed in public during 2014; (re-confirmed as current Agency need)		→ Ethylbenzene
Small evidence base (targeted update to address Agency need)		→ Chloroform
		Jason Fritz <i>National Center for Environmental Assessment</i>
		Larissa Pardo <i>National Center for Environmental Assessment</i>
		Paul Reinhart <i>National Center for Environmental Assessment</i>
		Ted Berner <i>National Center for Environmental Assessment</i>

*Draft assessment plans for 4 other multi-year agenda group 1 or 2 chemicals planned for 2018 public consultation 26

Open Discussion
